DOW JONES25,409.36-357.28 -1.39%
S&P 5002,954.22-24.54 -0.82%
NASDAQ8,567.37+0.89 0.01%

Baird Downgrades Vertex Pharmaceuticals to Neutral, Raises Price Target to $230

Baird analyst Brian Skorney downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Outperform to Neutral and raises the price target from $210 to $230.

Benzinga · 01/31/2020 11:53

Baird analyst Brian Skorney downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Outperform to Neutral and raises the price target from $210 to $230.